Published in Expert Rev Mol Diagn on January 01, 2010
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Ten questions about systems biology. J Physiol (2011) 1.36
Biomarkers for colorectal cancer. Int J Mol Sci (2010) 1.19
Exosomal miRNAs as Biomarkers for Prostate Cancer. Front Genet (2013) 1.06
Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. Front Genet (2012) 0.96
DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. Br J Cancer (2014) 0.93
MiR-141 Inhibits Gastric Cancer Proliferation by Interacting with Long Noncoding RNA MEG3 and Down-Regulating E2F3 Expression. Dig Dis Sci (2015) 0.91
Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int (2014) 0.91
Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate (2013) 0.89
siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer. PLoS One (2011) 0.89
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer (2012) 0.84
How to get the most from microarray data: advice from reverse genomics. BMC Genomics (2014) 0.84
Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease. Cancer Med (2013) 0.83
Biomarkers of postoperative delirium and cognitive dysfunction. Front Aging Neurosci (2015) 0.82
Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One (2013) 0.80
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget (2016) 0.78
Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes. Biomed Res Int (2015) 0.78
Clinically relevant genetic characterization of prostate tumors: how close are we to the goal? Korean J Urol (2015) 0.75
Insights into cancer mechanisms from genomic research on urological cancers. Genome Med (2011) 0.75
Multiplexed detection of molecular biomarkers with phase-change nanoparticles. Nanomedicine (Lond) (2013) 0.75
Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res (2004) 25.98
Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis (2006) 1.99
Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res (2005) 1.25
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Proteomics (2014) 0.95
Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol (2007) 0.94
Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. Int J Cancer (2011) 0.94
Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer (2010) 0.92
Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology (2006) 0.92
Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics (2007) 0.88
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2009) 0.87
Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer. Int J Cancer (2008) 0.83
Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells. PLoS One (2013) 0.82
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. BMC Cancer (2009) 0.80
Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium. Tumour Biol (2011) 0.77
Allelic deletions of Rb and L-myc in urine sediments from patients with bladder tumors or carcinoma in situ. Oncol Rep (2002) 0.75
[Genomic microarray technology. The Danish Society of Clinical Biochemistry]. Ugeskr Laeger (2008) 0.75
Are CIMP and chr16p13.2 copy-number status independent prognostic markers in stages II and III colorectal cancer? Int J Cancer (2011) 0.75